Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies-Reference-Cited by-同舟云学术

Combining cerebrospinal fluid and PI‐2620 tau‐PET for biomarker‐based stratification of Alzheimer's disease and 4R‐tauopathies

Published:2024-09-12 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Dilcher Roxane¹²^ORCID,Wall Stephan²,Groß Mattes³,Katzdobler Sabrina⁴⁵⁶,Wagemann Olivia⁵,Palleis Carla⁴⁵⁶,Weidinger Endy⁵,Fietzek Urban⁵,Bernhardt Alexander⁵⁶,Kurz Carolin⁷,Ferschmann Christian²,Scheifele Maximilian²,Zaganjori Mirlind²⁷,Gnörich Johannes²,Bürger Katharina³⁶,Janowitz Daniel³,Rauchmann Boris‐Stephan⁷⁸,Stöcklein Sophia⁹,Bartenstein Peter²,Villemagne Victor¹⁰¹¹,Seibyl John¹²,Sabri Osama¹³,Barthel Henryk¹³,Perneczky Robert⁴⁶⁷,Schöberl Florian⁵,Zwergal Andreas⁵¹⁴,Höglinger Günter U.⁴⁵⁶,Levin Johannes⁴⁵⁶,Franzmeier Nicolai³⁴¹⁵^ORCID,Brendel Matthias²⁴⁶

Affiliation:

1. Neuroscience Monash University Melbourne Australia

2. Department of Nuclear Medicine University Hospital of Munich LMU Munich München Germany

3. Institute for Stroke and Dementia Research University Hospital of Munich, LMU Munich München Germany

4. (SyNergy), Munich Cluster for Systems Neurology München Germany

5. Department of Neurology University Hospital of Munich, LMU Munich München Germany

6. (DZNE), German Center for Neurodegenerative Diseases München Germany

7. Department of Psychiatry and Psychotherapy University Hospital of Munich, LMU Munich München Germany

8. Institute for Neuroradiology University Hospital of Munich, LMU Munich München Germany

9. Department of Radiology University Hospital of Munich, LMU Munich München Germany

10. Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA

11. Department of Molecular Imaging & Therapy Austin Health Heidelberg Australia

12. Institute for Neurodegenerative Disorders New Haven Connecticut USA

13. Department of Nuclear Medicine University Hospital Leipzig Leipzig Germany

14. German Center for Vertigo and Balance Disorders (DSGZ) University Hospital of Munich, LMU Munich München Germany

15. Department of Psychiatry and Neurochemistry University of Gothenburg The Sahlgrenska Academy Institute of Neuroscience and Physiology Mölndal and Gothenburg Sweden

Abstract

AbstractINTRODUCTIONRecent advances in biomarker research have improved the diagnosis and monitoring of Alzheimer's disease (AD), but in vivo biomarker‐based workflows to assess 4R‐tauopathy (4RT) patients are currently missing. We suggest a novel biomarker‐based algorithm to characterize AD and 4RTs.METHODSWe cross‐sectionally assessed combinations of cerebrospinal fluid measures (CSF p‐tau181 and t‐tau) and 18F‐PI‐2620 tau‐positron emission tomography (PET) in patients with AD (n = 64), clinically suspected 4RTs (progressive supranuclear palsy or corticobasal syndrome, n = 82) and healthy controls (n = 19).RESULTSElevated CSF p‐tau181 and cortical 18F‐PI‐2620 binding was characteristic for AD while normal CSF p‐tau181 with elevated subcortical 18F‐PI‐2620 binding was characteristic for 4RTs. 18F‐PI‐2620‐assessed posterior cortical hypoperfusion could be used as an additional neuronal injury biomarker in AD.DISCUSSIONThe specific combination of CSF markers and 18F‐PI‐2620 tau‐PET in disease‐specific regions facilitates the biomarker‐guided stratification of AD and 4RTs. This has implications for biomarker‐aided diagnostic workflows and the advancement in clinical trials.Highlights

Novel biomarker‐based algorithm for differentiating AD and 4R‐tauopathies.

A combination of CSF p‐tau181 and 18F‐PI‐2620 discriminates AD versus 4R tauopathies.

Hypoperfusion serves as an additional neuronal injury biomarker in AD.

Funder

Monash University

Publisher

Wiley

Reference53 articles.

1. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes

2. Four-repeat tauopathies